New Xpert MTB/XDR: added value and future in the field. Issue 5 (19th November 2020)

• Record Type: Journal Article
• Authors: Bainomugisa, Arnold; Gilpin, Christopher; Coulter, Christopher; Marais, Ben J.
• Is Part Of: European respiratory journal. Volume 56:Issue 5(2020)
• Publication Date: 2020-11-19
• Subjects: Respiratory organs -- Diseases -- Periodicals; Respiration -- Periodicals; 616.2
• DOI: 10.1183/13993003.03616-2020
• Languages: English
• ISSNs: 0903-1936

Abstract

The recent launch of the new Xpert MTB/XDR assay (Cepheid Inc., Sunnyvale, CA, USA) by the Foundation for Innovative New Diagnostics [1] was widely welcomed by the tuberculosis (TB) community, given the critical need for new and better diagnostics to guide the treatment of drug resistant tuberculosis (DR-TB). Xpert MTB/XDR detects resistance to isoniazid (target genes: inhA promoter, katG, fabG1, oxyR-aphC intergenic region), ethionamide ( inhA promoter), fluoroquinolones ( gyrA and gyrB ), and second-line injectables ( rrs and eis promoter) and is positioned as an add-on or "reflex test" in patients with rifampicin resistance detected by Xpert MTB/RIF or Ultra [2, 3]. Xpert MTB/XDR is a new rapid molecular test for drug resistant tuberculosis https://bit.ly/3l2t4op